Navigation Links
PriceSpective Appoints Colasante as a Vice President and Murdoch as a Director

LONDON, Sept. 8 /PRNewswire/ -- PriceSpective, a value strategy consultancy that provides pricing and reimbursement services to pharmaceutical and biotechnology companies, is pleased to announce that it has hired two senior experts for its UK office. Walter Colasante, as a Vice President, and Sophie Murdoch, as a Director, will help further strengthen PriceSpective's pricing and reimbursement expertise and expand its current offerings.

Colasante, who brings 20 years experience in healthcare, will contribute to PriceSpective's real world pricing and reimbursement knowledge and client guidance, and will enhance PriceSpective's forecasting and portfolio and risk management services. Reflective of PriceSpective's promise of active senior level project involvement, Colasante will be an immediate resource for clients.

Expanding PriceSpective's commercial and device expertise, Murdoch brings 12 years of pharmaceutical experience. Murdoch will play a key role in developing strategic guidance for clients that synchronizes pricing and commercial goals.

"With ever-increasing pressure on drug pricing and debates over healthcare reforms across the globe," said CEO Steve Slovick, "we are delighted to bring on two, outstanding senior-level experts whose unique and diverse experiences will ensure the continuation of high quality services to our clients in a dynamic marketplace. Meanwhile, UK-based partner Keiron Sparrowhawk said, "Walter and Sophie will be invaluable in the continued growth and expansion of PriceSpective, enabling us to further meet our clients' needs."

Previously, Colasante was the founder and Managing Director of Freelance Heath Services, which specialised in pharmaceutical forecasting, business analysis and intelligence, market access planning and epidemiology. Colasante's previous consulting experience includes serving as a General Manager at The Mattson Jack Group and as a Senior Engagement Director at IMS. Colasante has also worked in clinical development for Novartis, Allergan and BMS.

Previously, Murdoch was an Associate Director at BMS, where she was responsible for developing the EMEA commercialization strategy for IXEMPRA. Before BMS, Murdoch was a Global Associate Director Hydrofiber Franchise at ConvaTec, a Marketing Manager at SSL International, and an International Product Manager at Smith & Nephew.

About PriceSpective

PriceSpective is a management consulting firm specializing in innovative strategies to identify, capture and communicate value for companies in the biopharmaceutical arena. We are uniquely positioned to deliver expert guidance in integrated global pricing, reimbursement and market access strategy due to our depth of experience and the active engagement of our senior leadership.

Over the last year, PriceSpective has climbed from position #413 on Inc 500's list of 'Fastest Growing Private Companies in America' to # 174. PriceSpective has offices in Los Angeles, Philadelphia and London and has a global staff of 49 professionals.

SOURCE PriceSpective
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. PriceSpective Continues Global Expansion With New San Diego Office
2. iPierian Appoints Dr. Matthew J. Plunkett as Chief Financial Officer
3. Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & Development
4. ERT Appoints New Associate Director of Business Development - Japan
5. NeurogesX Appoints New Board Director and Audit Committee Chairman
6. Orexigen(R) Therapeutics Appoints Mark Booth Chief Commercial Officer
7. Eiger BioPharmaceuticals Appoints Paul Truex to Board of Directors
8. Nucleix Appoints Meirav Chovav Vice President of Strategic Affairs and to the Board of Directors
9. Spectral appoints new board member
10. Cellular Dynamics International Appoints Leroy Hood, M.D., Ph.D., and George Church, Ph.D., to its Scientific Advisory Board
11. China Sky One Medical, Inc. Appoints New Independent Director
Post Your Comments:
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... San Francisco, CA (PRWEB) , ... June 23, ... ... capture (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase ... DIA Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... a new line of intelligent tools designed, tuned and optimized exclusively for Okuma ... 12–17 in Chicago. The result of a collaboration among several companies with expertise ...
Breaking Biology Technology:
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
(Date:3/22/2016)... PROVO and SANDY, ... Screening Ontario (NSO), which operates the highest sample volume ... testing, and Tute Genomics and UNIConnect, leaders in clinical ... today announced the launch of a project to establish ... testing panel. NSO has been contracted ...
Breaking Biology News(10 mins):